BIIBFDA Approval•prnewswire•
ALZHEIMER'S ASSOCIATION WELCOMES FDA ACTION APPROVING LEQEMBI WEEKLY SUBCUTANEOUS MAINTENANCE DOSING
Sentiment:Positive (75)
Summary
(NASDAQ:BIIB) CHICAGO, Aug. 29, 2025 /PRNewswire/ -- The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) action to approve weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early Alzheimer's disease. With this approval, Leqembi IQLIK is...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 29, 2025 by prnewswire